Table 3. HLA-DRB1 allele carrier frequency in RA patients and controls in subjects stratified for the presence of SE.
| RA (n = 1480) | Control (n = 800) | P | OR | 95%CI | ||
| *03 | SE negative | 1 (0.2) | 0 (0.0) | 0.4785 | 3.28 | (0.13–80.65) |
| SE positive | 1 (0.1) | 0 (0.0) | 1.0000 | 0.91 | (0.04–22.52) | |
| *04 other than SE | SE negative | 46 (10.3) | 81 (16.7) | 0.0055 | 0.58 | (0.39–0.85) |
| SE positive | 54 (5.2) | 34 (10.8) | 0.0010 | 0.45 | (0.29–0.71) | |
| *07 | SE negative | 5 (1.1) | 5 (1.0) | 1.0000 | 1.09 | (0.31–3.79) |
| SE positive | 5 (0.5) | 2 (0.6) | 0.6680 | 0.76 | (0.15–3.93) | |
| *08 | SE negative | 114 (25.6) | 140 (28.9) | 0.2703 | 0.85 | (0.64–1.13) |
| SE positive | 74 (7.1) | 41 (13.0) | 0.0018 | 0.51 | (0.34–0.77) | |
| *09 | SE negative | 230 (51.7) | 161 (33.2) | 1.44×10−8 | 2.15 | (1.65–2.81) |
| SE positive | 193 (18.6) | 52 (16.5) | 0.4051 | 1.16 | (0.83–1.62) | |
| *11 | SE negative | 17 (3.8) | 29 (6.0) | 0.1336 | 0.62 | (0.34–1.15) |
| SE positive | 23 (2.2) | 4 (1.3) | 0.3635 | 1.77 | (0.61–5.15) | |
| *12 | SE negative | 63 (14.2) | 66 (13.6) | 0.8496 | 1.05 | (0.72–1.52) |
| SE positive | 80 (7.7) | 21 (6.7) | 0.6248 | 1.17 | (0.71–1.93) | |
| *13 | SE negative | 48 (10.8) | 102 (21.0) | 2.43×10−5 | 0.45 | (0.31–0.66) |
| SE positive | 64 (6.2) | 32 (10.2) | 0.0235 | 0.58 | (0.37–0.91) | |
| *14 other than SE | SE negative | 63 (14.2) | 89 (18.4) | 0.0918 | 0.73 | (0.52–1.04) |
| SE positive | 72 (7.0) | 33 (10.5) | 0.0537 | 0.64 | (0.41–0.98) | |
| *15 | SE negative | 182 (40.9) | 207 (42.7) | 0.5950 | 0.93 | (0.72–1.21) |
| SE positive | 223 (21.5) | 55 (17.5) | 0.1305 | 1.30 | (0.94–1.80) | |
| *16 | SE negative | 10 (2.2) | 9 (1.9) | 0.8174 | 1.22 | (0.49–3.02) |
| SE positive | 7 (0.7) | 6 (1.9) | 0.0900 | 0.35 | (0.12–1.05) | |
| *13:01 | SE negative | 1 (0.2) | 7 (1.4) | 0.0712 | 0.15 | (0.02–1.26) |
| SE positive | 4 (0.4) | 1 (0.3) | 1.0000 | 1.22 | (0.14–10.94) | |
| *13:02 | SE negative | 47 (10.6) | 95 (19.6) | 0.0001 | 0.48 | (0.33–0.71) |
| SE positive | 60 (5.8) | 31 (9.8) | 0.0148 | 0.56 | (0.36–0.89) | |
| D70 | SE negative | 242 (54.4) | 320 (66.0) | 0.0004 | 0.61 | (0.47–0.80) |
| SE positive | 261 (25.2) | 114 (36.2) | 0.0002 | 0.59 | (0.45–0.78) | |
| I67 | SE negative | 301 (67.6) | 371 (76.5) | 0.0027 | 0.64 | (0.48–0.86) |
| SE positive | 390 (37.7) | 130 (41.3) | 0.2614 | 0.86 | (0.67–1.11) | |
| S1 | SE negative | 217 (48.8) | 288 (59.4) | 0.0012 | 0.65 | (0.50–0.84) |
| SE positive | 287 (27.7) | 87 (27.6) | 1.0000 | 1.01 | (0.76–1.33) | |
| D70 other than *13:02 | SE negative | 212 (47.6) | 253 (52.2) | 0.1892 | 0.83 | (0.64–1.08) |
| SE positive | 201 (19.4) | 83 (26.3) | 0.0092 | 0.67 | (0.50–0.90) | |
| I67 other than *13:02 | SE negative | 280 (62.9) | 310 (63.9) | 0.7852 | 0.96 | (0.73–1.25) |
| SE positive | 330 (31.9) | 99 (31.4) | 0.8904 | 1.02 | (0.78–1.34) | |
| S1 other than *13:02 | SE negative | 182 (40.9) | 213 (43.9) | 0.3536 | 0.88 | (0.68–1.15) |
| SE positive | 227 (21.9) | 56 (17.8) | 0.1147 | 1.30 | (0.94–1.80) |
RA: rheumatoid arthritis, SE: Shared epitope, OR: odds ratio, CI: confidence interval, Allele carrier frequencies are shown in parenthesis (%). Association was tested by Fisher's exact test using 2×2 contingency tables. SE negative: “A/A” or “A/other than SE or A” vs. “other than SE or A/other than SE or A”. SE positive: “SE/A” vs. “SE/other than A”. Allele groups SE, D70, I67, and S1 were as defined in the Materials and Methods section.